Hangzhou JINLAN Pharm-Drugs Technology Co., Ltd

Remdesivir, Oseltamivir phosphate, Arbidol HCl (Umifenovir HCl), Iohexol, Iopromide, Ioversol, Iopamidol, Iodixanol,Iomeprol, Gadobenate Dimeglumine, Gadopentetate monomeglumine, Fipronil, Calcitrol, Virginiamycin, Bicalutamide, Abiraterone acetate, Nepafenac, Vitamin D3,Sodium Dibunate, Mycophenolate mofetil, Mycophenolate Sodium (APIs,Intermediates,Biochemicals)

Product Certification

Hangzhou JINLAN Pharm-Drugs Technology Co., Ltd

Country:

China (Mainland)

Business Type:Trading Company

Diamond
supplier

Contacts

Fax:

URL: http://www.jlpharms.com

Province/state: Zhejiang

City: Hangzhou

Street:Rm A606, Fuyi Center, jianqiao street, Jianggan Area

E-MAIL Supplier Clike here

lower price CAS NO.763113-22-0

Min.Order: 0
Payment Terms:
Available Specifications:

Product Details

Keywords

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine

Quick Details

ProName: Olaparib cas
CasNo: 763113-22-0
Molecular Formula: C24H23FN4O3
ProductionCapacity: /
Purity: 99
LimitNum: 0

Superiority

Details

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is in for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.